CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it.
📊
Key Findings & Data:The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106 /kg.
💡
Conclusion & Impact:The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters
Abstract
Background/aim: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106 /kg. The aim of this study was to evaluate the relationship between the dose of CD34+ HPCs and survival in MM patients who underwent AHSCT at a tertiary care center. Materials and methods: Enrolled in this study were 271 MM patients who underwent AHSCT between 2003 and 2019. Clinical characteristics of the patients, disease status pre-AHSCT, reinfused CD34+ cell doses, and neutrophil and platelet engraftment days were recorded, retrospectively. The patients were divided into 2 groups according to whether the dose of reinfused CD 34+ HPCs was
🔖
Cite This Article
AKSU, S., BÜYÜKAŞIK, Y., GÖKER, H., DEMİROĞLU, H., ALADAĞ, E., SAYINALP, N., ÖZCEBE, O. İ., HAZNEDAROĞLU, İ. C., TURGUT, M. (2022). CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 8, 1851–1856. https://ajindex.com/articles/609746
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE et al. Medical Research Council Adult Leukaemia Working P: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine 2003
348 (19): 1875-1883. doi:10.1056/NEJMoa022340 2. Şahin U, Demirer T. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma. Journal of Clinical Apheresis 2018
33 (3): 357-370. doi: 10.1002/jca.21591 3. Stiff PJ, Micallef I, Nademanee AP, Stadtmauer EA, Maziarz RT et al. Transplanted CD34(+) cell dose is associated with longterm platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biology of Blood Marrow Transplantation 2011
17 (8): 1146-1153.doi: 10.1016/j. bbmt.2010.11.021 4. Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin BE et al. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Medical Oncology 2012
29 (3): 2191-2199. doi:10.1007/ s12032-011-0029-3 5. Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells and Developments 2004
13 (6): 598-606.doi:10.1089/ scd.2004.13.598 6. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation 2010
16 (4): 490-499. doi:10.1016/j.bbmt.2009.11.012 7. Solmaz Medeni Ş, Türkyılmaz D, Acar C, Sevindik OG, Yüksel Fet al. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment? Turkish Journalof Hematology 2018
35 (4): 271-276.doi: 10.4274/tjh.2018.0071 8. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009
23 (10): 1904-1912.doi: 10.1038/leu.2009.127 9. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. American journal of hematology 2018
93 (8): 981-1114.doi:10.1002/ajh.25117 10. Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G et al. Guidelines for the dia